|
2025
|
Invention
|
Engineered cancer antigens and related methods and uses. Provided are engineered cancer antigens ... |
|
|
Invention
|
Virus encoding transgenes to complement cellular therapy.
An oncolytic group B adenovirus suitab... |
|
2024
|
Invention
|
Adenovirus armed with bispecific t cell activator.
A modified adenovirus, in particular Enadenot... |
|
|
Invention
|
Group b adenovirus-containing formulation.
The present disclosure relates to formulations suitab... |
|
|
Invention
|
Oncolytic adenoviruses armed with heterologous genes.
The present disclosure relates to a group ... |
|
2023
|
Invention
|
Group b adenovirus encoding an anti-tcr-complex antibody or fragment.
The present disclosure rel... |
|
|
Invention
|
Adenovirus armed with bispecific t cell activator.
An adenovirus comprising a sequence of formul... |
|
|
P/S
|
Biological preparations for the diagnosis and treatment of oncological diseases and disorders; bi... |
|
|
P/S
|
Pharmaceutical preparations and substances for the treatment of oncological diseases and disorder... |
|
2022
|
Invention
|
Virus encoding transgenes to complement cellular therapy. An oncolytic group B adenovirus suitabl... |
|
|
Invention
|
Virus encoding transgenes to complement cellular therapy |
|
|
Invention
|
Adenovirus encoding il-15.
A group B adenovirus comprising a sequence of formula 5′ITR—B1-BA-B2-... |
|
|
Invention
|
Adenovirus encoding 1l-15. A group B adenovirus comprising a sequence of formula 5'ITR-B1-BA-B2-B... |
|
2021
|
Invention
|
Dosing regime and formulations for type b adenoviruses. 12 particles per minute. The disclosure f... |
|
2020
|
Invention
|
Oncolytic adenoviruses armed with heterologous genes. 5′ITR-B1-BA-B2-BX-BB-BY-B3-3′ITR wherein: B... |
|
|
Invention
|
Method of purifying a composition comprising a group b adenovirus.
A method of purifying a compo... |
|
2019
|
Invention
|
Group b adenovirus-containing formulation. The present disclosure provides a liquid formulation s... |
|
2018
|
Invention
|
Oncolytic adenovirus encoding a b7 protein or active fragment. The present disclosure provides a ... |
|
|
Invention
|
Adenovirus armed with bispecific t cell activator. Y comprises a transgene cassette containing fo... |
|
|
Invention
|
Adenovirus armed with bispecific t cell activator. An adenovirus comprising a sequence of formula... |
|
|
P/S
|
Pharmaceutical preparations and substances. Research and development services in the field of imm... |
|
|
P/S
|
Research and development services in the field of immunology, biotechnology, oncology, medicine a... |
|
|
P/S
|
pharmaceutical preparations and substances. Research and development services in the field of imm... |
|
|
Invention
|
Oncolytic virus and method. An oncolytic virus (for example a replication competent virus) compri... |
|
|
P/S
|
Pharmaceutical research and development services in the field of immunology, biotechnology, oncol... |
|
2017
|
Invention
|
Adenovirus armed with bispecific t cell engager. A modified adenovirus, in particular Enadenotuci... |
|
|
Invention
|
Oncolytic group b adenovirus expressing a stroma-targeted bispecific t-cell engager. A modified a... |
|
|
Invention
|
Adenovirus armed with bispecific t cell activator. A modified adenovirus, in particular Enadenotu... |
|
|
Invention
|
Oncolytic adenovirus encoding a therapeutic protein or active fragment. The present disclosure pr... |
|
2016
|
Invention
|
Group b adenovirus encoding an anti-tcr-complex antibody or fragment. The present disclosure rela... |
|
|
Invention
|
Virus encoding an anti-tcr-complex antibody or fragment. The present disclosure relates to a repl... |
|
|
Invention
|
Oncolytic adenovirus encoding a b7 protein. The present disclosure provides a replication compete... |
|
2015
|
Invention
|
Group b adenovirus modified in the e4orf4 region. 3-3′ITR (I).
|
|
2014
|
Invention
|
Method of making adenovirus and corresponding plasmids. The present disclosure relates to a metho... |
|
|
Invention
|
Oncolytic adenoviruses armed with heterologous genes. The present disclosure relates to a group B... |
|
|
Invention
|
Oncolytic adenoviruses armed with heterologous genes. The present disclosure relates to a g... |
|
|
Invention
|
Chimeric adenoviruses for use in cancer treatment. The present invention relates to oncolytic ade... |
|
|
Invention
|
Dosing regime and formulations for type b adenovirus. 12 particles per minute. Also provided are ... |
|
|
Invention
|
A dosing regime and formulations for type b adenoviruses. The present disclosure provides a metho... |
|
|
Invention
|
A dosing regime and formulations for type b adenoviruses.
The present disclosure provi... |
